XML 46 R35.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Revenue - Disaggregation of Revenue by Product (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Disaggregation of Revenue [Line Items]        
Revenue $ 11,302.8 $ 8,312.1 $ 20,070.8 $ 15,272.1
U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 7,835.2 5,531.4 13,529.6 9,967.6
Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 3,467.5 2,780.7 6,541.2 5,304.6
Cardiometabolic Health        
Disaggregation of Revenue [Line Items]        
Revenue 7,514.6 5,010.9 13,007.6 9,201.3
Cardiometabolic Health | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 5,716.1 3,781.4 9,806.1 6,856.4
Cardiometabolic Health | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 1,798.5 1,229.5 3,201.6 2,344.9
Mounjaro®        
Disaggregation of Revenue [Line Items]        
Revenue 3,090.8 979.7 4,897.4 1,548.2
Mounjaro® | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 2,413.7 915.7 3,934.0 1,452.2
Mounjaro® | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 677.2 64.0 963.4 96.0
Trulicity®        
Disaggregation of Revenue [Line Items]        
Revenue 1,245.6 1,812.5 2,701.9 3,789.6
Trulicity® | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 876.7 1,371.3 1,958.6 2,918.7
Trulicity® | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 368.9 441.2 743.3 871.0
Zepbound®        
Disaggregation of Revenue [Line Items]        
Revenue 1,243.2 0.0 1,760.6 0.0
Zepbound® | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 1,243.2 0.0 1,760.6 0.0
Zepbound® | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 0.0 0.0 0.0 0.0
Jardiance        
Disaggregation of Revenue [Line Items]        
Revenue 769.6 668.3 1,456.1 1,245.8
Jardiance | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 428.9 386.1 797.1 715.6
Jardiance | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 340.7 282.2 659.0 530.2
Humalog®        
Disaggregation of Revenue [Line Items]        
Revenue 631.6 440.4 1,170.3 901.4
Humalog® | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 434.7 229.8 773.0 501.4
Humalog® | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 196.9 210.6 397.3 400.0
Humulin®        
Disaggregation of Revenue [Line Items]        
Revenue 223.6 205.3 429.8 457.3
Humulin® | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 169.3 144.3 322.4 343.1
Humulin® | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 54.2 61.0 107.4 114.2
Basaglar®        
Disaggregation of Revenue [Line Items]        
Revenue 180.8 154.2 338.3 363.5
Basaglar® | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 105.2 83.0 188.4 218.4
Basaglar® | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 75.6 71.2 149.9 145.2
Baqsimi        
Disaggregation of Revenue [Line Items]        
Revenue 12.4 613.9 11.5 645.4
Baqsimi | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 3.3 606.2 (6.9) 629.3
Baqsimi | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 9.0 7.7 18.3 16.1
Other cardiometabolic health        
Disaggregation of Revenue [Line Items]        
Revenue 117.0 136.6 241.7 250.1
Other cardiometabolic health | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 41.1 45.0 78.9 77.7
Other cardiometabolic health | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 76.0 91.6 163.0 172.2
Oncology        
Disaggregation of Revenue [Line Items]        
Revenue 2,158.7 1,671.0 3,968.7 3,027.0
Oncology | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 1,275.2 935.0 2,273.5 1,688.4
Oncology | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 883.5 736.0 1,695.1 1,338.6
Verzenio®        
Disaggregation of Revenue [Line Items]        
Revenue 1,331.9 926.8 2,382.2 1,677.7
Verzenio® | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 861.4 588.6 1,499.6 1,049.6
Verzenio® | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 470.5 338.2 882.6 628.0
Cyramza®        
Disaggregation of Revenue [Line Items]        
Revenue 248.9 260.3 478.7 497.0
Cyramza® | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 116.1 115.0 223.3 215.6
Cyramza® | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 132.8 145.3 255.4 281.4
Erbitux®        
Disaggregation of Revenue [Line Items]        
Revenue 155.8 162.5 300.4 292.4
Erbitux® | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 142.9 145.5 275.0 264.2
Erbitux® | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 13.0 17.0 25.4 28.1
Tyvyt®        
Disaggregation of Revenue [Line Items]        
Revenue 123.0 103.6 239.7 164.6
Tyvyt® | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 0.0 0.0 0.0 0.0
Tyvyt® | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 123.0 103.6 239.7 164.6
Other oncology        
Disaggregation of Revenue [Line Items]        
Revenue 299.1 217.8 567.7 395.3
Other oncology | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 154.8 85.9 275.6 159.0
Other oncology | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 144.2 131.9 292.0 236.5
Immunology        
Disaggregation of Revenue [Line Items]        
Revenue 1,082.4 928.5 1,916.3 1,706.3
Immunology | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 599.8 523.1 996.9 877.6
Immunology | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 482.6 405.4 919.4 828.6
Taltz®        
Disaggregation of Revenue [Line Items]        
Revenue 824.7 703.9 1,428.8 1,230.8
Taltz® | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 539.4 472.3 886.4 784.5
Taltz® | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 285.3 231.6 542.3 446.3
Olumiant®        
Disaggregation of Revenue [Line Items]        
Revenue 227.7 218.9 445.1 447.8
Olumiant® | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 44.5 50.8 90.9 93.1
Olumiant® | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 183.2 168.1 354.2 354.6
Other immunology        
Disaggregation of Revenue [Line Items]        
Revenue 30.0 5.7 42.4 27.7
Other immunology | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 15.9 0.0 19.6 0.0
Other immunology | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 14.1 5.7 22.9 27.7
Neuroscience        
Disaggregation of Revenue [Line Items]        
Revenue 339.5 387.2 728.6 747.7
Neuroscience | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 191.9 160.9 355.1 305.4
Neuroscience | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 147.6 226.3 373.5 442.3
Emgality®        
Disaggregation of Revenue [Line Items]        
Revenue 192.0 169.3 417.8 323.6
Emgality® | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 137.6 118.8 262.7 227.5
Emgality® | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 54.4 50.5 155.1 96.1
Other neuroscience        
Disaggregation of Revenue [Line Items]        
Revenue 147.5 217.9 310.8 424.1
Other neuroscience | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 54.3 42.1 92.4 77.9
Other neuroscience | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 93.2 175.8 218.4 346.2
Other        
Disaggregation of Revenue [Line Items]        
Revenue 207.6 314.6 449.6 589.9
Other | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 52.2 131.0 98.0 239.8
Other | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 155.4 183.5 351.6 350.1
Cialis®        
Disaggregation of Revenue [Line Items]        
Revenue 87.7 115.6 227.1 215.9
Cialis® | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 7.5 9.2 13.4 16.8
Cialis® | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 80.2 106.4 213.7 199.1
Forteo®        
Disaggregation of Revenue [Line Items]        
Revenue 69.9 148.0 131.2 270.3
Forteo® | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 31.5 97.4 53.2 168.0
Forteo® | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 38.5 50.6 78.0 102.3
Other        
Disaggregation of Revenue [Line Items]        
Revenue 50.0 51.0 91.3 103.7
Other | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 13.2 24.4 31.4 55.0
Other | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue $ 36.7 $ 26.5 $ 59.9 $ 48.7